Psoriasis, biological drugs and Coronavirus Disease 2019: Real life experience of two Italian provinces
On January 30, 2020, World Health Organization (WHO) stated that a new coronavirus disease outbreak [COronaVIrus Disease - 19 (COVID-19)] was an international public health emergency. Many news, often fake ones, about the derived pandemic rapidly spread along the media, thus leading many dermatological patients to identify as “risk category” and sometimes discontinue treatments by themselves. The Dermatology Units in Grosseto and Pordenone simultaneously carried out a data collection by remote-conducted visits, evaluating the incidence of COVID-19 in psoriatic patients. Only 1 patient (close contact of a case) as part of the psoriasis analyzed group was tested and turned out to be positive for SARS-CoV-2, developing no symptoms during the observation period. The collected information may suggest that psoriasis, biotechnologically treated or not, cannot promote or aggravate the clinical trend of the SARS-CoV-2 infection, hence stopping systemic therapy in negative or clinically free SARS-CoV-2 patients is not recommended in general.
Public Health Emergency of International Concern (PHEIC) - (World Health Organization (WHO). Statement on the second meeting of the International Health Regulations (2 0 0 5). Emergency Committee regarding the outbreak of novel coronavirus (201 9 - nCoV).
Lambert TW, Soskolne CL, Bergum V et al. Ethical perspectives for public and environmental health:fostering autonomy and the right to know. Environ Health Perspect 2003 Feb; 111(2): 133–137.
- Abstract views: 414
- PDF: 277
- HTML: 0
Copyright (c) 2020 The Authors
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.